Company · Healthtech & Bio

Telum Therapeutics

telumtherapeutics.com ↗ ·Noáin ·Series A

Telum Therapeutics is a clinical-stage biotechnology company developing next-generation antimicrobial therapies based on engineered phage lytic proteins and antimicrobial peptides, using its proprietary APEXp platform that combines metagenomic datasets (including bacteriophages harvested from unexplored caves), synthetic biology and generative AI. Its lead program targets hospital-acquired and ventilator-associated bacterial pneumonia caused by multidrug-resistant Acinetobacter baumannii and Pseudomonas aeruginosa. Founded in Navarra in 2019, it is headquartered in Noáin (Pamplona metro area) with a US entity in New York, and closed an €18M Series A in mid-2026 led by the AMR Action Fund; Dr. Subhendu Basu became CEO in 2024, with founder Roberto Díez-Martínez moving to COO.

Founded
2019
Founders
2
News
13
Rounds
2
Investors
8
SectorsBiotech, Antimicrobials / Anti-infectives, Drug Discovery, Synthetic Biology, AI in Drug Development Start-up MapHealthtech & Bio › Drug discovery & therapeutics developers

Profile updated 11 Aug 2026

Founders

Roberto Díez-Martínez
Co-founder & Chief Operating Officer (founding CEO; President, Telum Therapeutics Inc.)
Rubén Díez Punzano
Co-founder & Chief Financial Officer
—

Global models

No comparables on record yet.

Investors 8

AMR Action Fund
www.amractionfund.com ↗
Investor United States
CDTI Innvierte
www.cdti.es
Investor Spain
Clave Capital
clavemayor.com
Investor Spain
Investor Spain
Investor Spain
Inveready
inveready.com
Investor Spain
Invivo Partners
invivo.partners
Investor Spain
SODENA
www.sodena.com
Investor Spain

Funding rounds 2

Series A · €18M
Endolysin-antimicrobials biotech secured an €18M Series A co-led by the AMR Action Fund and Inveready to take its lead candidate against dru…
2026-06-30
Seed · €4.1M
Telum Therapeutics raised €4.1M in its first round to develop enzybiotics, which are therapies based on bacteriophage lytic enzymes, against…
2020-07-13

News & media 13

PublishedArticle
2026-08-03 Julio consolida un verano récord en inversión: 672,85M€ en 38 operaciones ↗
El Referente
2026-07-20 España coinvierte 96 millones en un mes para ayudar a escalar a la deeptech española ↗
Conecta Industria
2026-07-16 CDTI Innvierte destina en junio €96M a 7 nuevas coinversiones en capital riesgo y 1 vehículo de inversión ↗
Webcapitalriesgo
2026-07-02 Telum raises €18M to push phage-derived antimicrobials toward clinic ↗
European Biotechnology Magazine
2026-07-01 La navarra Telum Therapeutics cierra una ronda de 18 millones liderada por AMR Action Fund ↗
Navarra Capital
2026-07-01 Telum Therapeutics raised €18 million to advance treatments for hospital-acquired infections ↗
EU-Startups
2025-03-31 Telum Therapeutics, Complutense University of Madrid and Carlos III Health Institute discover next-generation antimicrobials against vancomycin-resistant E. faecium ↗
Telum Therapeutics (press release)
2025-02-25 Telum Bolsters APEXp Platform with 'TelClo System' Patent Filing ↗
Telum Therapeutics (press release)
2025-01-28 Telum Therapeutics Joins BEAM Alliance to Combat Antimicrobial Resistance ↗
Telum Therapeutics (press release)
2024-12-24 Telum Therapeutics Announces Filing of New Patent for Antimicrobial Peptides ↗
Telum Therapeutics (press release)
2024-04-04 Telum Therapeutics joins the United Nations Global Compact ↗
Telum Therapeutics (press release)
2024-03-19 Telum Therapeutics appoints Dr. Subhendu Basu as CEO ↗
PR Newswire
2024-02-12 Telum Therapeutics earns EcoVadis badge for corporate sustainability ↗
Telum Therapeutics (press release)
Start typing to search across everything.
↑↓ navigate↵ openesc close